UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

Clinical cancer research, 2019-03, Vol.25 (6), p.1727-1736

2019

Volltextzugriff (PDF)

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

Molecular cancer therapeutics, 2012-05, Vol.11 (5), p.1133-1142

2012

Volltextzugriff (PDF)

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

Blood advances, 2018-04, Vol.2 (8), p.848-858

2018

Volltextzugriff (PDF)

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

Cancer research (Chicago, Ill.), 2010-03, Vol.70 (6), p.2528-2537

2010

Volltextzugriff (PDF)

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Journal of hematology and oncology, 2017-01, Vol.10 (1), p.13-13, Article 13

2017

Volltextzugriff (PDF)

A Novel Electrochemiluminescence (ECL) Immunoassay for the Quantitation of Monoclonal Antibody (mAb) PYX-106 in Human Serum

Current analytical chemistry, 2024-01, Vol.20 (6), p.438-448

2024

Volltextzugriff (PDF)

572 PYX-102, an anti-KLRG1 antibody, enhances cytotoxic activity of CD8-T-cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A649-A649

2023

Volltextzugriff (PDF)

Mutation of the Murine Bloom's Syndrome Gene Produces Global Genome Destabilization

Molecular and Cellular Biology, 2006-09, Vol.26 (17), p.6713-6726

2006

Volltextzugriff (PDF)

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

Nature (London), 2010-11, Vol.468 (7320), p.103-107

2010

Volltextzugriff (PDF)

Dual inactivation of Hus1 and p53 in the mouse mammary gland results in accumulation of damaged cells and impaired tissue regeneration

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (50), p.21282-21287

2009

Volltextzugriff (PDF)

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Bioconjugate chemistry, 2017-05, Vol.28 (5), p.1371-1381

2017

Volltextzugriff (PDF)

Bcl-2-Mediated Cell Survival Promotes Metastasis of EpH4 βMEKDD Mammary Epithelial Cells

Molecular cancer research, 2004-10, Vol.2 (10), p.551-556

2004

Volltextzugriff (PDF)

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

Neoplasia (New York, N.Y.), 2016-12, Vol.18 (12), p.775-784

2016

Volltextzugriff (PDF)

Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC–MS/MS approach

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023-05, Vol.1223, p.123715-123715, Article 123715

2023

Volltextzugriff (PDF)

A sensitive and rapid LC-MS/MS assay for quantitation of free payload Aur0101 from antibody drug conjugate (ADC) PYX-201 in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023-07, Vol.1226, p.123786-123786, Article 123786

2023

Volltextzugriff (PDF)

Abstract 1373: Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1373-1373

2024

Volltextzugriff (PDF)

Abstract 2908: EDB+FN is an attractive therapeutic target in oncology: Insights from protein expression analysis of solid tumors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2908-2908

2024

Volltextzugriff (PDF)

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

Molecular cancer therapeutics, 2015-07, Vol.14 (7), p.1605-1613

2015

Volltextzugriff (PDF)

Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023-08, Vol.1228, p.123844-123844, Article 123844

2023

Volltextzugriff (PDF)

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML

Molecular cancer therapeutics, 2018-06, Vol.17 (6), p.1271-1279

2018

Volltextzugriff (PDF)

Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies

Journal of pharmaceutical and biomedical analysis, 2023-09, Vol.233, p.115452-115452, Article 115452

2023

Volltextzugriff (PDF)

An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities

Molecular cancer therapeutics, 2020-08, Vol.19 (8), p.1660-1669

2020

Volltextzugriff (PDF)

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Molecular cancer therapeutics, 2021-01, Vol.20 (1), p.203-212

2021

Volltextzugriff (PDF)

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia (New York, N.Y.), 2016-12, Vol.18 (12), p.775-784

2016

Volltextzugriff (PDF)

Abstract 3898: Preclinical evaluation of DM21, a next-generation maytansinoid payload with a stable peptide linker

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3898-3898

2019

Volltextzugriff (PDF)

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(138)
Tschechisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

A Novel Electrochemiluminescence (ECL) Immunoassay for the Quantitation of Monoclonal Antibody (mAb) PYX-106 in Human Serum

572 PYX-102, an anti-KLRG1 antibody, enhances cytotoxic activity of CD8-T-cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins

Mutation of the Murine Bloom's Syndrome Gene Produces Global Genome Destabilization

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

Dual inactivation of Hus1 and p53 in the mouse mammary gland results in accumulation of damaged cells and impaired tissue regeneration

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Bcl-2-Mediated Cell Survival Promotes Metastasis of EpH4 βMEKDD Mammary Epithelial Cells

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC–MS/MS approach

A sensitive and rapid LC-MS/MS assay for quantitation of free payload Aur0101 from antibody drug conjugate (ADC) PYX-201 in human plasma

Abstract 1373: Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication

Abstract 2908: EDB+FN is an attractive therapeutic target in oncology: Insights from protein expression analysis of solid tumors

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML

Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies

An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Abstract 3898: Preclinical evaluation of DM21, a next-generation maytansinoid payload with a stable peptide linker

Suchergebnisse filtern